dept header
Directory | Contact
 

Clinical Trials

If you have additional questions, please contact Audrey Sorensen, RN Trials Coordination Thoracic Oncology 212-263-2562

  1. E5597: Phase III Chemoprevention trial of selenium supplementation in persons with resected stage I non small cell lung cancer
    Objective: Use of selenium in preventing tumor growth in patients with previously resected Stage I Non Small Cell Lung Cancer. The primary objective is to evaluate the efficacy of selenium supplementation in reducing the incidence of second primary lung tumors in patients who have been treated for Stage I NSCLC with complete surgical resection. Patients are eligible for this study if they are post complete resection of stage IA or IB NSCLC who are currently free of disease.
    Investigator(s): Harvey Pass
  2. A Breath Test for Lung Cancer
    Objective: The primary objective is to demonstrate that in clinical practice, the breath test could provide a safe and non-invasive ancillary test for primary.
    Investigator(s): Harvey Pass & William Rom
  3. A Phase III trial of lobectomy versus sublobar resection for small (<2cm) peripheral non small cell lung cancer
    Objective: The objective is to determine whether disease free survival after sublobar resection (segmentectomy or wedge) is inferior to that after lobectomy in ...
    Investigator(s): Harvey Pass
  4. 109493: A double Blind, Randomized, Placebo controlled phase III study to Assess the efficacy of recMAGE-A3 + AS15 Antigen specific cancer immunothera...
    Objective: Primary objective is to demonstrate the clinical efficacy to recMAGE-A3 + AS15 versus placebo in NSCLC after complete resection. Secondary objective ...
    Investigator(s): Sylvia Adams

  5. Source MdX: Lung Cancer Biomarker Study Early Detection and Prognosis
    Objective: A project involving the collection of blood samples and sample related clinical data in a collaborative research project with Source MdX for an early detection and prognosis Lung Cancer Biomarker Study.

  6. Title: A Prospective Multi Center Randomized Clinical Trial to Evaluate the PleuraSeal Sealant System as an Adjunct to Standard Closure Techniques for Control of Visceral Air Leaks Following Elective Pulmonary Resection via Open Thoracotomy
    Objective: To evaluate the safety and effectiveness of the PleuraSeal sealant system in the treatment and control of intra and postoperative air leaks following pulmonary resection via an open thoracotomy.


  7. Title:An Open Label Clinical Trial of MORAb-009 in Combination with Pemetrexed and Cisplatin in Subjects with Mesothelioma
    Objective:To determine the effect on progression-free survival of adding MORAB-009 to the combination of Pemetrexed and Cisplatin in the treatment of subjects with unresectable malignant pleural mesothelioma who have not received prior systemic therapy.


  8. Title :A Phase II Trial of Stereotactic Body Radiation Therapy (SBRT) in the Treatment of Patients with Operable Stage I/II Non-Small Cell Lung Cancer
    Objective: To determine whether radiotherapy involving high biological dose with limited treatment volume (using SBRT techniques) achieves acceptable local control (i.e. greater than 90% at 2 years in operable patients with early stage NSCLC)


  9. Randomized Phase II trial of Erlotinib with or without PF-3512676 for the treatment of patients with advanced EGFR-Positive NSCLC after failure of at least one prior chemotherapy regimen.
    Objective:Erlotinib is a drug that blocks the epidermal growth factor receptor (EGFR). Epidermal growth factor receptors (EGF receptors) are molecules present on the surface of certain cancer cells. These receptors play a role in the growth of cancer cells and blocking the receptor may slow or stop the growth of some cancer cells.

    Erlotinib is approved for the treatment of non-small cell lung cancer in patients whose disease has progressed following treatment with chemotherapy based on results from a large clinical study comparing erlotinib plus supportive care to supportive care alone

    PF-3512676 is a new drug that has been shown to boost the immune system. It has already been tested in approximately 1000 patients with various types of cancer in the United States, Canada, and Europe. Early clinical data suggest that in combination with standard chemotherapy, PF-3512676 may be able to improve the outcome for patients with advanced non-small cell lung cancer.

  10. Title: A Phase 2, Open Label Study of IMC-1121 B in Combination with Paclitaxel and Carboplatin as First-line Therapy in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer
    Objective: We believe that IMC-1121B blocks the activity of growth factors made by the cancer cells, so new blood vessels do not grow. It is believed that without the new blood vessels, the cancer or tumor will not get the oxygen and nutrients that it needs to grow. This may stop the cancer from growing or spreading and the tumor cells may die. Since normal blood vessels have already formed in adults, it might be possible to stop tumor growth without harming normal cells.